NASDAQ · LGND
Healthcare · Biotechnology
$322.75
Up+$5.42 (+1.71%)
Updated Oct 31, 2026, 7:08 PM
SID Score
5.9/10
Composite research score
Smart Money
58/100
Neutral
Price performance · LGND
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
LGND closed at $322.75 after 21 trading sessions, up 6.53% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $319.22 | $324.90 | $314.505 | $322.75 | 344.31K |
| Oct 29, 2026 | $315.15 | $323.8248 | $309.63 | $317.33 | 299.39K |
| Oct 28, 2026 | $311.62 | $319.90 | $309.69 | $318.78 | 268.47K |
| Oct 27, 2026 | $308.51 | $314.19 | $307.55 | $311.73 | 143.35K |
| Oct 26, 2026 | $304.39 | $309.43 | $303.47 | $308.30 | 194.78K |
| Oct 23, 2026 | $307.82 | $313.28 | $302.37 | $303.53 | 366.55K |
| Oct 22, 2026 | $313.00 | $315.2725 | $305.34 | $307.82 | 315.14K |
| Oct 21, 2026 | $305.36 | $317.64 | $303.9301 | $314.78 | 222.76K |
| Oct 20, 2026 | $298.61 | $314.05 | $298.61 | $306.40 | 171.73K |
| Oct 19, 2026 | $300.41 | $303.855 | $295.735 | $297.28 | 117K |
| Oct 16, 2026 | $297.67 | $297.67 | $292.56 | $295.54 | 164.51K |
| Oct 15, 2026 | $298.18 | $304.6003 | $296.85 | $298.50 | 332.11K |
| Oct 14, 2026 | $299.55 | $307.11 | $292.28 | $294.99 | 245.28K |
| Oct 13, 2026 | $311.72 | $311.72 | $300.23 | $303.53 | 203.31K |
| Oct 12, 2026 | $302.50 | $311.86 | $300.00 | $311.13 | 173.18K |
| Oct 9, 2026 | $294.79 | $304.775 | $294.315 | $301.81 | 183.05K |
| Oct 8, 2026 | $290.41 | $296.48 | $281.7401 | $295.00 | 318.88K |
| Oct 7, 2026 | $293.63 | $301.265 | $292.47 | $293.26 | 309.24K |
| Oct 6, 2026 | $309.41 | $309.41 | $293.725 | $296.94 | 163.74K |
| Oct 5, 2026 | $303.95 | $309.77 | $300.7851 | $306.77 | 163.82K |
| Oct 2, 2026 | $307.55 | $307.63 | $301.32 | $302.96 | 179.23K |
The latest Smart Investors Daily articles mentioning LGND.
Company
Market Activity
Research & News
LGND research
Company profile and research snapshot.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 30, 2026 | RBC Capital | Outperform | — |
| Sep 25, 2026 | Barclays | Overweight | — |
| Sep 24, 2026 | HC Wainwright & Co. | Buy | — |
| Sep 23, 2026 | Citigroup | Buy | — |
| Aug 14, 2026 | Leerink Partners | Outperform | — |
No generated briefing is available yet.
Benzinga · Oct 23, 2026
Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 20 years by 12.04% on an annualized basis producing an average annual return of 20.96%. Currently, Ligand Pharmaceuticals has a market
Yahoo · Oct 15, 2026
JUPITER, Fla., Oct. 15, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (Nasdaq: LGND) today announced that it will report third quarter 2026 financial results on Thursday, October 29, 2026. The company will hold a conference call beginning at 8:30 a.m. Eastern time to discuss the results and provide a general business update. Conference Call and Webcast Information Date:Thursday, October 29, 2026 Time:8:30 a.m. Eastern time Conference Call:United States (Local): +1 (585) 542-9983 U
Benzinga · Oct 13, 2026
Ligand Pharmaceuticals (NASDAQ:LGND) has outperformed the market over the past 15 years by 13.64% on an annualized basis producing an average annual return of 26.84%. Currently, Ligand Pharmaceuticals has a market
Benzinga · Oct 7, 2026
On Thursday, Ligand Pharmaceuticals (NASDAQ:LGND) discussed second-quarter financial results during its earnings call. The full transcript is provided below. Benzinga APIs provide real-time access to earnings call
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LGND.
